Field Name	Field Description
Prior	
<u>Authorization</u>	Encelto
Group	
<u>Description</u>	Empelto (nevelino gene to nevete el lever)
Drugs Covered Uses	Encelto (revakinagene taroretcel-lwey) Medicelly accepted indications are defined using the following
<u>Covered Uses</u>	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex,
	American Hospital Formulary Service (AHFS), United States
	Pharmacopeia Drug Information for the Healthcare Professional
	(USP DI), the Drug Package Insert (PPI), or disease state specific
	standard of care guidelines.
Exclusion Criteria	N/A
Required Medical	See "other criteria"
<u>Information</u>	
Age Restrictions	According to package insert
<u>Prescriber</u>	Prescriber must an ophthalmologist or specialist in the treatment of
Restrictions	macular telangiectasia (MacTel) type 2
Coverage	If all criteria are met, the request will be approved for a single
<u>Duration</u>	implant per eye per lifetime.
Other Criteria	**Drug is being requested through the member's medical benefit**
	 Confirmed diagnosis of idiopathic MacTel type 2 Inner segment (IS)/outer segment (OS) photoreceptor (PR) break (loss) in ellipsoid zone (EZ) between 0.16 and 2.00 mm² measured by spectral domain-optical coherence tomography (SD-OCT) Best corrected visual acuity (BCVA) score of 54 letters or better (20/80 or better Snellen equivalent) measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart Prescriber attests that member has no evidence of neovascular MacTel type 2 Member has not previously received an Encelto implant for treated eye
Revision/Review Date: 7/2025	***Reauthorizations are not permitted, as members are limited to a single implant per eye per lifetime.***
	Medical Director/clinical reviewer may override criteria when, in his/her professional judgement, the requested item is medically necessary.